Free Trial
NASDAQ:QDEL

QuidelOrtho Q2 2025 Earnings Report

QuidelOrtho logo
$27.57 -0.38 (-1.36%)
Closing price 04:00 PM Eastern
Extended Trading
$27.56 0.00 (-0.02%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

QuidelOrtho EPS Results

Actual EPS
N/A
Consensus EPS
$0.01
Beat/Miss
N/A
One Year Ago EPS
N/A

QuidelOrtho Revenue Results

Actual Revenue
N/A
Expected Revenue
$612.36 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

QuidelOrtho Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Wednesday, July 30, 2025
Conference Call Time
5:00PM ET

Conference Call Resources

QuidelOrtho Earnings Headlines

Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.
QuidelOrtho Corporation (QDEL) - Yahoo Finance
See More QuidelOrtho Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like QuidelOrtho? Sign up for Earnings360's daily newsletter to receive timely earnings updates on QuidelOrtho and other key companies, straight to your email.

About QuidelOrtho

QuidelOrtho (NASDAQ:QDEL) (NASDAQ:QDEL) is a leading developer, manufacturer and marketer of in vitro diagnostic healthcare solutions headquartered in San Diego, California. Through its integrated Quidel and Ortho Clinical Diagnostics business units, the company provides clinicians, laboratories and healthcare providers with rapid diagnostic, molecular testing and blood screening products designed to support patient care and public health initiatives.

The Quidel business unit specializes in immunoassays and molecular diagnostics, offering a broad portfolio of rapid antigen, antibody and molecular tests for infectious diseases, including its proprietary Sofia, Solana and Lyra platforms. Quidel’s assays cover respiratory, gastrointestinal, sexually transmitted and women’s health pathogens, empowering on-the-spot and high-complexity laboratories with fast and accurate results. The company’s molecular instruments, such as the Solana and AmpliVue systems, feature simplified workflows and versatile assay menus that address emerging public health threats.

Through Ortho Clinical Diagnostics, QuidelOrtho delivers transfusion medicine and serology solutions, fielding the VITROS immunodiagnostic system for hospital and reference laboratories worldwide. Ortho’s portfolio includes blood typing, antibody screening and confirmatory tests that ensure safe blood transfusions and immunology diagnostics. The combined organization benefits from complementary research and development capabilities, expanding its pipeline of assays and enhancing manufacturing scale.

Tracing its roots to the 1979 founding of Quidel and the more than 70-year heritage of Ortho Clinical Diagnostics, QuidelOrtho serves customers in over 130 countries. Under the leadership of President and Chief Executive Officer Douglas Bryant, the company maintains manufacturing facilities across North America and Europe and operates a global distribution network. QuidelOrtho continues to invest in innovation, aiming to address evolving healthcare challenges and strengthen its role in diagnostic medicine.

View QuidelOrtho Profile

More Earnings Resources from MarketBeat